Literature DB >> 2994029

A search for new antihypertensive agents. I. Alpha-adrenergic activity and selection of structures among pyrazine substituted imidazolines.

R Kaliszan, H Foks, B Damasiewicz, A Nasal, A Radwańska, W Kuźmierkiewicz, D Pancechowska-Ksepko, W Rudnicka, K Wisterowicz.   

Abstract

A group of new pyrazinylimidazolines was prepared and their effect on the contraction of isolated rat tail artery as well as their effect on blood pressure in urethane anesthetized normotensive rats were tested. The biological responses were compared to those elicited by standard imidazoline drugs and structure-activity relationships were analysed. The new chemical derivatives were subsequently synthetized and tested pharmacologically. Basing on the experimental results obtained and comparing these to the reported data on arylimidazolines the following suggestions have been put forward concerning the further modifications of alpha-adrenergically active pyrazinylimidazolines: 1) a distance of about 5 A should separate imidazoline nitrogen and pyrazine nucleus, 2) bond refractivity of the separating bridge should be above 5.33, 3) hydrophobicity of substituents in pyrazine ring must be possibly high.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2994029

Source DB:  PubMed          Journal:  Pol J Pharmacol Pharm        ISSN: 0301-0244


  3 in total

1.  Antiaggregatory activity of imidazoline drugs and chemicals as a function of their structure.

Authors:  J Petrusewicz; R Kaliszan
Journal:  Agents Actions       Date:  1988-06

2.  Structure and alpha-adrenergic activity of pyrazinimidazolines.

Authors:  R Kaliszan; B Damasiewicz; A Nasal; A Radwańska; H Foks; W Kuźmierkiewicz; D Pancechowska-Ksepko; K Rudnicka; K Wisterowicz; K Ośmiałowski
Journal:  Agents Actions       Date:  1985-07

3.  Meta-Analysis Based on Nonconvex Regularization.

Authors:  Hui Zhang; Shou-Jiang Li; Hai Zhang; Zi-Yi Yang; Yan-Qiong Ren; Liang-Yong Xia; Yong Liang
Journal:  Sci Rep       Date:  2020-04-01       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.